Irdai asks insurers to review claims denied for antibody cocktail therapy

IRADI said it had come across instances where claims were denied/ there was a deduction in expenses incurred towards "antibody cocktail therapy", under the pretext that it's an experimental treatment

The Insurance Regulatory and Development Authority of India (Irdai) has asked general and health insurance companies to review the claims related to “antibody cocktail therapy” for Covid-19 which were denied by them.

In a circular dated January 7, addressed to the chief executive officers (CEOs) of the general and health insurance companies, the regulator has said, “ … insurers are advised to review the claims denied/ deductions made in such claims and take appropriate action